SABSW SAB BIOTHERAPEUTICS INC C/WTS 22/10/2026 (TO PUR COM)
- 0.0492
- +0.0019+4.02%
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference
Express News | SAB Biotherapeutics Inc - SAB-142 on Track for Topline Phase 1 Data Readout by Year-End
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
Express News | SAB Bio Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting
Express News | SAB Bio Announces Second Quarter 2024 Financial Results and Provides Company Updates
10-Q: Q2 2024 Earnings Report
Express News | SAB Bio Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes
Express News | SAB Bio Appoints Lucy to as Chief Financial Officer
SAb Biotherapeutics Rebrands as SAB BIO
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
Express News | SAB Bio Confirms 2024 Fiscal Outlook
Express News | SAB Bio's CFO Michael King to Depart
Express News | SAB Biotherapeutics Announces Departure of Chief Financial Officer
Express News | FDA Provides Clearance to Ind Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics
Express News | SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates
10-Q: Q1 2024 Earnings Report
Express News | SAB Biotherapeutics Appoints Jay Skyler, Md, to the Board of Directors
Express News | SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics to Present at INNODIA Annual Meeting
SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference